Note M - Segment Information

12 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

M. Segment Information

Our business consists of three segments for financial reporting purposes. The three segments are identified as (i) private label contract manufacturing, which primarily relates to the provision of private label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, and (ii) patent and trademark licensing, which primarily includes royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnosSyn® trade name, and (iii) branded products, which relates to the marketing and distribution of our branded nutritional supplements and consists primarily of the products sold under our Pathway to Healing^® product line.

Due to the steady decline in sales of our Pathway to Healing^® product line over the prior several years, we decided to discontinue the product line. Pursuant to the License Agreements, Dr. Cherry and Cherry Ministries licensed to NAI the name, likeness, style, persona and other attributes of Dr. Cherry in connection with the sale of nutritional products that were marketed by NAI under its Pathway to Healing brand. Pursuant to the License Agreements, NAI was permitted to terminate the License Agreements by written notice at any time. We have notified Dr. Cherry and Cherry Ministries of our decision to discontinue the product line and the termination of the related license agreement was effective as of September 15, 2014. We anticipate that all termination activities related to the Pathway to Healing^® product line will be complete by the end of our second quarter of fiscal 2015. We did not change the financial presentation in this report to reflect the branded products segment as “Discontinued Operations” as the wind down of this product line did not meet the criteria for discontinued operations presentation as prescribed by ASC 205-20.

We evaluate performance based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before corporate allocations. Operating income or loss for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to: human resources, corporate legal, finance, information technology, and other corporate level related expenses, which are not allocated to any segment. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note A.

Our operating results by business segment for the years ended June 30 were as follows (in thousands):

	2014		2013
Net Sales
Private-label contract manufacturing	$	67,339	$	56,672
Patent and trademark licensing		5,444		4,799
Branded products		1,159		1,326
	$	73,942	$	62,797

	2014			2013
Operating Income
Private-label contract manufacturing	$	5,559		$	5,137
Patent and trademark licensing		2,281			1,519
Branded products		(235	)		67
Income from operations of reportable segments		7,605			6,723
Corporate expenses not allocated to segments		(4,828	)		(4,570	)
	$	2,777		$	2,153

	2014		2013
Total Assets
Private-label contract manufacturing	$	50,424	$	45,032
Patent and trademark licensing		1,632		1,388
Branded products		202		220
	$	52,258	$	46,640

Our private-label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Canada, Mexico, Australia, South Africa and Asia. Our primary market outside the U.S. is Europe. Our patent and trademark licensing activities are primarily based in the U.S. and our branded products are only sold in the U.S.

Net sales by geographic region, based on the customers’ location, for the two years ended June 30 were as follows (in thousands):

	2014		2013
United States	$	38,729	$	36,710
Markets outside the United States		35,213		26,087
Total net sales	$	73,942	$	62,797

Products manufactured by NAIE accounted for 57% of net sales in markets outside the U.S. in fiscal 2014 and 67% in fiscal 2013. No products manufactured by NAIE were sold in the U.S. during the fiscal years ended June 30, 2014 and 2013.

Assets and capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, for the two years ended June 30 were as follows (in thousands):

2014	Long-Lived Assets		Total Assets		Capital Expenditures
United States	$	6,648	$	36,618	$	2,297
Europe		2,163		15,640		382
	$	8,811	$	52,258	$	2,679

2013	Long-Lived Assets		Total Assets		Capital Expenditures
United States	$	6,728	$	32,450	$	838
Europe		2,477		14,190		783
	$	9,205	$	46,640	$	1,621